Bonnie L. Bassler - Mar 24, 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**Bonnie L. Bassler
Stock symbol
REGN
Transactions as of
Mar 24, 2023
Transactions value $
-$541,942
Form type
4
Date filed
3/27/2023, 04:43 PM
Previous filing
Feb 7, 2023
Next filing
Mar 31, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $472K +1.24K +99.44% $380.95 2.49K Mar 24, 2023 Direct F1
transaction REGN Common Stock Sale -$1.01M -1.24K -49.86% $818.00 1.25K Mar 24, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1.24K -33.33% $0.00 2.48K Mar 24, 2023 Common Stock 1.24K $380.95 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022.
F2 The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.